EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report
Cancer Reports · 2026
DOI: 10.1002/cnr2.70444 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Yanan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science Research Project of Hebei.
Abstract (Originalsprache)
Background
Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M/p. S768I mutations that were associated with prolonged stable disease after treatment with IHPC, especially following furmonertinib‐based treatment. Case A 47‐year‐old Chinese female patient was admitted to a regional cancer hospital and presented with malignant pleural effusion (MPE). The TNM and clinical stages were identified as T2aN2M1c and IVB, respectively. The TPS value is 40%. IHP combined with chemotherapy was then carried out to remove MPE. For first‐stage treatment, three cycles of afatinib‐based adjuvant chemotherapy beginning in September 2022 were given, and the degree of pleural effusion on the left side of the chest was not reduced. The best response (BOR) assessment of the local lesion was a partial response (PR). Furmonertinib‐based adjuvant monotherapy was performed from May 2023 to July 2024. The BOR evaluation results during the monotherapy courses were all judged as SD.
Conclusion
The EGFR p.V774M/p.The S768I mutation contributed to improving the efficiency of furmonertinib‐based therapy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei, China.
ORCID-Profile: Zizheng Song, Ling Hu
Förderung
- Medical Science Research Project of Hebei
Zitieren
APA
Wang, Y., Ren, G., Song, Z., Hu, L., Li, W., & Wang, X. (2026). EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70444
Vancouver
Wang Y, Ren G, Song Z, Hu L, Li W, Wang X. EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report. Cancer Reports. 2026. doi:10.1002/cnr2.70444
BibTeX
@article{Wang2026,
author = {Wang, Yanan and Ren, Guanying and Song, Zizheng and Hu, Ling and Li, Weiqi and Wang, Xiaolei},
title = {EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70444}
}
EUVIMED